Exposure-Response Relationships in Patients with Non-Small-Cell Lung Cancer and Other Solid Tumors Treated with Patritumab Deruxtecan (HER3-DXd).

ABSTRACT: Patritumab deruxtecan (HER3-DXd, also known as MK-1022), an antibody-drug conjugate consisting of a human epidermal growth factor receptor 3 (HER3) antibody attached to a topoisomerase I inhibitor payload (DXd), has demonstrated efficacy in patients with metastatic breast cancer and non-small cell lung cancer (NSCLC). Exposure-efficacy was assessed in 446 patients with EGFR-mutated NSCLC; exposure-safety was assessed in 715 patients with NSCLC, breast cancer, or colorectal cancer. A range of HER3-DXd dosing regimens was evaluated, including fixed-dosing regimens (1.6-8 mg/kg every 3 weeks [Q3W]; 3.2-6.4 mg/kg Q3W), an up-titration dosing regimen, and an alternative Q2W/Q3W dosing regimen. Logistic regression or time-to-event models were used to test the relationships of each endpoint with

SUBMITTER: Li L 

PROVIDER: S-EPMC12272309 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature